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Abstract
Introduction: Homozygosity for interleukin-6 (IL-6) 174G_C promoter polymorphism has recently been associated with indices of meta-
bolic syndrome; however, this problem has not been investigated in non-obese subjects.
The aim of this study was to explore the relation between abdominal fat distribution and some inflammatory risk factors of atheromatosis
and IL-6 174G_C gene polymorphism in non-obese healthy subjects.
Material and methods: Relationships were investigated between anthropometric variables, i.e. weight, height, BMI, waist circumference
(WC), waist-to-hip ratio (WHR), body fat distribution (DXA), serum CRP and IL-6, insulin sensitivity/resistance indices, and IL-6 174G_C
gene polymorphism, in healthy non-obese Polish subjects: 232 women (age 31.4 ± 5.5 years) and 199 men (age 30.3 ± 6.0 years).
Results: The genetic study revealed that the CC genotype was observed in 15.56% of subjects, the CG genotype in 52.74%, and the GG
genotype in 31.7%. IL-6 and CRP concentration did not differ among the genotypes. There were also no differences regarding BMI and
WHR. The only differences among genotypes, observed only in men, were those concerning total fat (CC had higher fat content than CG
and GG); the difference being statistically significant between CC and GG (p < 0.05), and gynoidal fat deposit (CC had higher gynoidal fat
deposit than CG and GG); the difference being statistically significant between CC and GG (p < 0.025) and between CC and CG (p < 0.05).
Biochemical parameters and insulin sensitivity did not differ among the genotypes.
Conclusions: These data show that IL-6 174G_C polymorphism is not associated with features describing metabolic syndrome in non-
obese healthy subjects. (Pol J Endocrinol 2009; 60 (3): 172–179)
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Streszczenie
Wstęp: W ostatnim czasie pojawiły się doniesienia na temat związku polimorfizmu 174G_C genu interleukiny 6 (IL-6) z wskaźnikami
zespołu metabolicznego. Jednak problem ten nie był badany u osób z należną masą ciała.
Celem opisanych badań było znalezienie związku między zawartością tkanki tłuszczowej brzusznej a wybranymi zapalnymi czynnikami
ryzyka rozwoju miażdżycy i polimorfizmem 174G_C genu IL-6 u zdrowych osób z należną masą ciała.
Materiał i metody: Badano związek między cechami antropometrycznymi, takimi jak: masa ciała, wzrost, wskaźnik masy ciała (BMI, body
mass index), obwód talii, stosunek obwodu talii do obwodu bioder (WHR, waist-to-hip index), dystrybucja tkanki tłuszczowej (DXA), stęże-
niem białka C-reaktywnego (CRP, C-reactive protein)  i IL-6 oraz wskaźnikami insulinowrażliwości/oporności a polimorfizmem 174G_C IL-
6. Grupę badaną stanowiło 232 zdrowe nieotyłe kobiety (wiek 31,4 ± 5,5 lat) oraz 199 mężczyzn (wiek 30,3 ± 6,0 lat).
Wyniki: Autorzy stwierdzili, że genotyp CC występował u 15,56%, CG u 52,74%, a GG u 31,7% badanych. Stężenia IL-6 i CRP nie różniły
się pomiędzy genotypami. Nie było także różnic odnośnie BMI i WHR. Jedyne różnice pomiędzy genotypami, widoczne tylko w grupie
mężczyzn dotyczyły całkowitej zawartości tkanki tłuszczowej (genotyp CC wykazywał większą zawartość tłuszczu niż CG i GG), różnica
ta była istotna statystycznie między CC a GG (p < 0,05), oraz  depozytu gynoidalnego (wyższe wartości u genotypu CC niż u CG i GG),
różnica ta była istotna statystycznie między CC a GG (p < 0,025) oraz między CC i CG (p < 0,05). Parametry biochemiczne i wrażliwość na
insulinę nie różniły się pomiędzy genotypami.
Wnioski: Uzyskane wyniki wskazują na brak związku między polimorfizmem 174G_C IL-6 a zaburzeniami metabolicznymi u osób zdro-
wych z należną masą ciała. (Endokrynol Pol 2009; 60 (3): 172–179)
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Obesity is a well-known risk factor of cardiovascular
diseases, type 2 diabetes, and some neoplasms. Excessi-
ve fat accumulation, especially in the abdominal region,
is accompanied by metabolic disturbances such as in-
sulin resistance, dyslipidemia, increased levels of inflam-
matory markers, and higher blood pressure. All these
disturbances significantly increase the risk of develo-
ping atherosclerosis and cardiovascular diseases.
It is known that insulin resistance and hyperinsuli-
naemia play important roles in the pathogenesis of obe-
sity-related consequences. Interleukin 6 (IL-6) is one of
the cytokines that can modulate insulin sensitivity and
energy balance [1]. Some studies have described a link
between IL-6 174G_C promoter polymorphism and BMI
[2, 3]. Berthier et al. [4] reported that the 174CC variant
was associated with indices of obesity, while Kubaszek
et al. [1] observed an association of increased BMI and
the –174C allele, which, however, was non-significant.
In humans, the effect of 174G_C promoter polymor-
phism of the IL-6 gene on fat distribution has not been
studied. Therefore, we investigated the effect of this
polymorphism not only on BMI and insulin sensitivity,
but also on anthropometric features characterizing fat
distribution in 431 healthy, non-obese young subjects.
Material and methods
The study was performed in 232 healthy, non-obese
(BMI [body mass index] < 30 kg/m2) women and 199 men
aged 20–40 years, who were randomly selected from
among Wroclaw’s citizens. This group was part of an
ongoing epidemiological study. Exclusion criteria were
chronic diseases requiring special diet or treatment with
anti-diabetic or lipid lowering drugs, neoplasmatic dis-
eases, and, in women, use of oral contraceptives or
a period shorter than three months after withdrawal
from oral contraceptives. Subjects with infections were
excluded at the physical examination stage.
The study protocol was approved by the Ethics
Committee of Wroclaw Medical University, and all the
subjects gave their informed consent in writing.
All the subjects were interviewed and a physical
examination was carried out, which included arterial
blood pressure and anthropometrical measurements
such as body mass, body height, and waist circumfe-
rence. The BMI was calculated from the equation: BMI
= body mass [kg]/height-squared [m2]. The waist-to-hip
ratio was defined as waist circumference divided by hip
circumference. Body mass and height were measured
without top clothing and shoes; waist circumference
was measured halfway between the costal angle and
the iliac crests. The percentage of body fat and visceral
fat deposit were assessed using the dual-energy X-ray
absorptiometry method (DXA) using a “DPX (+) Lu-
nar” device (USA). The percentage of abdominal fat (an-
droid fat deposit) was calculated using a computerized
method after measuring fat tissue volume in the area
from the upper edge of the L2 to the lower edge of the L4
vertebrae. Gynoid fat deposit was calculated after measu-
ring fat volume in the area between the trochanter major
of the femur and the knees.
Peripheral venous blood samples were collected
between 7:00 and 9:00 a.m. after overnight fasting, and
the plasma was stored immediately after centrifugation
at — 80°C until assay.
IL-6 was measured by ultra-sensitive enzyme-linked
immunosorbent assay – ELISA (BioSource). Intra-Assay
precision was 4.71% CV and Inter-Assay precision was
6.7% CV.
Glucose level, total cholesterol, HDL cholesterol, and
triglycerides were measured using commercially ava-
ilable kits, and LDL levels were calculated using the
Friedewald formula [5]. Fasting insulin was measured
using an immunoenzymatic method (Abbott Diagno-
stics, USA). The insulin sensitivity index (QUICKI) and
the insulin resistance indices (HOMA and FIRI) were





All the study participants were genotyped for IL-6
174G/C promoter polymorphism. Genomic DNA was
extracted from human blood leukocytes using a Blood
Mini Kit (A&A, Biotechnology) according to the manu-
facturer’s recommendation.
Genotyping of promoter –174G/C (rs1800795) po-
lymorphism of the IL-6 gene was carried out by poly-
merase chain reaction - restriction fragment length po-
lymorphism (PCR-RFLP) analysis as described previo-
usly (9) with our own modification. A 198-bp fragment
of the IL-6 gene was amplified. The forward and re-
verse primer sequences were IL-6-174F: 5’-TGA CTT
CAG CTT TAC TCT TTG-3’ and IL-6-174R: 5’-CTG ATT
GGA AAC CTT ATT AAG-3’ (Proligo), respectively. The
reaction was carried out in a final volume of 10 mL con-
taining 2 mL of Q-Solution (Qiagen), 2.25 mL of sterile
double distilled water, 2 mL of PCR Buffer (containing
15 mM MgCl2, Qiagen), 0.25 mL of each dNTP (Fer-
mentas), 0.8 mL of each primer, 5 U/mL Taq DNA poly-
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merase (Qiagen), and 1 mL of genomic DNA. DNA was
denatured for 2 minutes at 95∞C and then subjected to
40 amplification cycles. Each PCR cycle consisted of
denaturation for 30 seconds at 95∞C, annealing for
30 seconds at 60∞C, and extension for 30 seconds at
72∞C; followed by a final extension at 72∞C for 5 minu-
tes. Hold step at 4∞C forever. 10 mL of 198 bp PCR pro-
ducts were digested with 10 U/mL LweI (SfaNI, Fermen-
tas) restriction enzyme in a total volume of 20 mL (2 mL
of Buffer Tango with BSA, Fermentas and 7.7 mL of
sterile double distilled water) at 37∞C overnight, incu-
bated with 4 mL of SYBERGreen for 15 minutes, and
then separated by electrophoresis on 2% agarose gel.
The presence of a single 198 — bp band corresponded
to CC homozygotes, bands at 140 bp and 58 bp were
related to GG homozygots, and the presence of all three
bands represented GC heterozygots. Genotypes were
confirmed separately by two experienced technicians
assigned to the study.
Statistical analysis
Data are presented as means and standard devia-
tions (SD). A nonparametric Mann-Whitney U test and
Kolmogorov-Smirnov test were used to compare gro-
ups of genotypes. The minimal level of significance was
fixed at p < 0.05 for all procedures. Results of borderli-
ne significance (0.05 < p < 0.1) were also taken into
consideration. The statistical analysis was performed
using Statistica 6.0 software.
Results
Table I presents the baseline characteristics of the
study group. We observed that 25.87% of the whole
group were overweight (BMI > 25 kg/m2), the percen-
tage of overweight women being 8.66%, and men
45.96%. Higher values of waist circumference, above the
recommended 80 cm for women and 94 cm for men,
Table I. Baseline characteristics (mean, SD) of the study participants
Tabela I. Wyjściowa charakterystyka (średnia, SD) uczestników badania
Whole group (431) Women (232) Men (199)
Age (years) 30.93 (5.72) 31.4 (5.47) 30.34 (5.98)
Weight [kg] 67.93 (13.57) 58.7 (7.85) 79.4 (9.93)
Height [cm] 171.8 (9.36) 165.23 (5.62) 179.88 (6.16)
BMI [kg/m2] 22.88 (3.1) 21.48 (2.54) 24.61 (2.85)
Waist circumference [cm] 79.39 (11.19) 71.84 (6.64) 89.06 (7.92)
Hip circumference [cm] 99.99 (6.62) 97.87 (5.94) 102.93 (6.41)
WHR 0.79 (0.09) 0.73 (0.05) 0.87 (0.07)
Systolic BP [mm Hg] 110.31 (14.46) 107 (13.46) 114.49 (14.64)
Diastolic BP 72.5 (10.37) 69.52 (9.56) 76.25 (10.16)
BMI — body mass index; WHR — waist-to-hip ratio
Table II. Lipid profile, glucose, insulin, and indices of insulin sensitivity/resistance in the study group
Tabela II. Profil lipidowy, stężenie glukozy, insuliny i wskaźniki wrażliwości/oporności na insulinę w badanej grupie
Whole group (431) Women (232) Men (199)
Total cholesterol [mg/dl] 193.62 (35.8) 188.79 (31.19) 199.53 (40.04)
Triglycerides [mg/dl] 79.64 (51.9) 64.46 (34.33) 98.33 (62.76)
HDL-C [mg/dl] 64.87 (16.59) 70.77 (15.62) 57.64 (14.83)
LDL-C [mg/dl] 112.72 (34.08) 105.1 (29.02) 122.37 (37.48)
Glucose [mg/dl] 82.09 (8.68) 79.72 (7.77) 85.03 (8.88)
Insulin [µIU/ml] 6.811 (3.76) 5.95 (3.65) 7.892 (3.63)
HOMA 1.393 (0.8) 1.17 (0.73) 1.669 (0.81)
QUICKI 0.376 (0.04) 0.39 (0.04) 0.363 (0.03)
FIRI 1.254 (0.72) 1.06 (0.66) 1.502 (0.73)
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were observed in 10.82% of the women and 17.68% of
the men. Although we excluded obese subjects (with
BMI ≥ 30 kg/m2) from the study, we found visceral obe-
sity (according to the IDF criteria) in 0.43% of the wo-
men and 3.53% of the men.
Table II summarizes the data on lipid profile, gluco-
se, insulin, and insulin sensitivity/resistance indices in
the study group. Impaired fasting glucose was observed
in 1.69% of the subjects, with 0.873% of the women and
2.717% of the men.
The genetic study revealed that the CC genotype
was observed in 15.56%, the CG genotype in 52.74%,
and the GG genotype in 31.7% in the subjects of our
study group. The G and C allele frequencies were 58%
and 42%, respectively.
IL-6 and CRP concentrations did not differ among
the genotypes (Table III). There were also no differen-
ces regarding BMI and WHR (Table IV). The only diffe-
rences among genotypes, observed only in men, were
those concerning total fat (CC had higher fat content
than CG and GG carriers), the difference being statisti-
cally significant between CC and GG (p < 0.05), and
gynoidal fat deposit (CC had higher gynoidal fat depo-
sit than CG and GG), the difference being statistically
significant between CC and GG (p < 0.025), and betwe-
en CC and CG (p < 0.05). These results are shown in
Table IV. There were no differences in lipid concentra-
tions, glucose levels, or insulin sensitivity/resistance in-
dices among genotypes. These results are summarized
in Table V.
Discussion
All the study participants were genotyped for IL-6
174G_C promoter polymorphism, with 15.56% having
the CC, 31.7% the GG, and 52.74% the CG genotypes.
The G and C allele frequencies were 58% and 42%,
respectively. The allele frequencies are similar to tho-
se reported in previous studies for European whites
[2–4, 10, 11].
In the late nineties a study by Fishman et al. on the
biological relevance of IL-6 174G_C promoter polymor-
phism indicated that the C allele resulted in a lower IL-
6 gene expression than the G allele [9], suggesting that
average IL-6 concentrations might be lower in subjects
with the homozygous (CC) genotype. In addition, in
a study by Terry et al., CC genotype was shown to be
a weaker inducer of IL-6 gene expression than the G
allele [12]. However, later studies in humans gave con-
tradictory results [3, 13, 14]. In our study, IL-6 and CRP
plasma levels were not significantly different among the
genotypes of the IL-6 174G_C promoter polymorphism
(Table 3), which is in accordance with the observations















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































It has been shown that many tissues, including adi-
pose tissue, secrete IL-6, and that the levels of IL-6 cor-
relate with BMI [16, 17]. There are also some studies in-
dicating a link between IL-6 174G_C promoter polymor-
phism and BMI or other obesity indices [2, 3], especially
in men [4]. However, although we observed slightly hi-
gher values of BMI and WHR in male carriers of the
C allele, we did not find significant differences regarding
BMI or WHR among the genotypes. A similar observa-
tion was made by other authors [1, 15, 17, 18].
There are interesting data demonstrating that ge-
netic factors, among them IL-6 174G_C promoter poly-
morphism, may account for differences in therapeutic
response to laparoscopic adjustable gastric binding
(LAGB). Sesti et al. investigated the impact of IL-6
174G_C promoter polymorphism on weight loss in
morbidly obese subjects after LAGB and a hypocaloric
diet, showing that carriers of the GG genotype lost more
weight than those with the CG or CC genotype [19].
This study shows that IL-6 174G_C promoter polymor-
phism may play an important role in the regulation of
body weight. What is more, 174G_C promoter polymor-
phism of the IL-6 gene influences energy expenditure:
subjects with the CC genotype of the IL-6 gene had si-
gnificantly lower energy expenditure than subjects with
the CG or GG genotypes, both in fasting and during
the euglycaemic hyperinsulinemic clamp [1].
The results of Cardellini et al. indicate that the GG
genotype of the IL-6 gene may contribute to variations
in insulin sensitivity, resulting in impaired insulin sen-
sitivity [18].
Increasing evidence suggests that low-grade inflam-
mation, which is observed in obesity [20, 21], could be
one of the determinants in the pathogenesis of insulin
resistance and type 2 diabetes [22, 23]. Although there
is one study showing a relationship between insulin
resistance and IL-6 concentrations in non-obese subjects
[24], in most cases elevated plasma and adipose tissue
levels of IL-6 have been associated with insulin resistan-
ce, but in an obese state [23, 25]. This may explain why
in our study of healthy non-obese subjects we did not
observe any relationship between IL-6 174G_C promo-
ter polymorphism and insulin resistance.
Conclusions
In conclusion, our data show that IL-6 174G_C poly-
morphism is not associated with features describing
metabolic syndrome in non-obese healthy subjects.
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